Provided by Tiger Trade Technology Pte. Ltd.

Mineralys Therapeutics, Inc.

29.77
+1.565.53%
Post-market: 30.580.8100+2.72%19:49 EST
Volume:1.58M
Turnover:46.69M
Market Cap:2.36B
PE:-10.40
High:30.19
Open:28.98
Low:28.42
Close:28.21
52wk High:47.65
52wk Low:8.24
Shares:79.14M
Float Shares:55.73M
Volume Ratio:1.37
T/O Rate:2.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8636
EPS(LYR):-3.6632
ROE:-42.14%
ROA:-26.50%
PB:4.09
PE(LYR):-8.13

Loading ...

Mineralys Therapeutics Inc call volume above normal and directionally bullish

TIPRANKS
·
Jan 24

Chief Medical Officer David Malcom Rodman Reports Sale of Mineralys Therapeutics Inc. Common Shares

Reuters
·
Jan 21

Mineralys Therapeutics (MLYS) Valuation After Q3 Beat And Lorundrostat NDA Progress

Simply Wall St.
·
Jan 19

Mineralys Therapeutics CEO Jon Congleton Reports Disposal of Common Shares

Reuters
·
Jan 14

CFO Adam Scott Levy Sells Common Shares of Mineralys Therapeutics Inc

Reuters
·
Jan 14

Mineralys Targets Sleep Apnea and Hypertension With Lorundrostat: What Investors Should Watch

TIPRANKS
·
Jan 14

Mineralys Therapeutics Inc - Filed Nda for Lorundrostat to U.S. FDA in Late 2025

THOMSON REUTERS
·
Jan 06

Mineralys Therapeutics Inc - Co Remains on Track to Report Topline Results From Phase 2 Explore-Osa Trial in Q1 2026

THOMSON REUTERS
·
Jan 06

Mineralys Therapeutics Submits NDA for Lorundrostat to FDA

Reuters
·
Jan 06

Did JAMA’s “Research of the Year” Spotlight on Lorundrostat Just Shift Mineralys Therapeutics’ (MLYS) Investment Narrative?

Simply Wall St.
·
Dec 21, 2025

Mineralys Therapeutics Inc : Bofa Global Research Raises Price Objective to $46 From $43

THOMSON REUTERS
·
Dec 19, 2025

How Investors May Respond To Mineralys Therapeutics (MLYS) After $287.5 Million Upsized Capital Raise and New Institutional Backing

Simply Wall St.
·
Dec 01, 2025

BRIEF-Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Nov 27, 2025

Director and 10% Owner Brian Taylor Slingsby Reports Disposal of Mineralys Therapeutics Inc. Common Shares

Reuters
·
Nov 22, 2025

Mineralys Therapeutics Q3 EPS USD -0.52

Reuters
·
Nov 20, 2025

Mineralys Therapeutics Shares Fall Following Executives' Stock Sale

MT Newswires Live
·
Nov 15, 2025

Mineralys Therapeutics falls -13.9%

TIPRANKS
·
Nov 14, 2025

Mineralys Therapeutics Director Daphne Karydas Reports Disposal of Common Shares

Reuters
·
Nov 14, 2025

Evercore ISI Keeps Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)

TIPRANKS
·
Nov 12, 2025

Stock Track | Mineralys Therapeutics Soars 5.22% as Multiple Analysts Raise Price Targets

Stock Track
·
Nov 11, 2025